Amedisys Reports Fourth Quarter and Year End 2021 Financial Results; Issues 2022 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Amedisys (AMED) Reports In-Line Q4 EPS
February 23, 2022 4:09 PM ESTAmedisys (NASDAQ: AMED) reported Q4 EPS of $1.18, in-line with the analyst estimate of $1.18. Revenue for the quarter came in at $559.3 million versus the consensus estimate of $555.2 million.
GUIDANCE:
Amedisys sees FY2022 EPS of $5.23-$5.45, versus the consensus of $5.84. Amedisys sees... More
